Separate names with a comma.
Discussion in 'Sunovion' started by Anonymous, Jun 2, 2011 at 9:15 AM.
Lunesta is going generic sooner than any of you know....stay tuned
Old news late 2013 or early 2014 sorry to give you the facts
I think the original post may be onto something....restructure timed with Teva news. Interesting.
That's why the company just dedicated 350 to sell it only, because they think its going generic in the next year-got it. Your inside info is impressive, the Teva letter is just what they do.
Here is a link to the actual FDA approval letter. Make of it what you will.
A quote from the FDA approval letter:
"You also notified the agency of a consent judgment resulting inthe dismissal of this case. This dismissal ends the 7½-yearstay of approval, which had previously been in effect pursuantto sections 505(j)(5)(B)(iii) and 505(j)(5)(F)(ii) of the Act"
And the consent judgement says TEVA cannot sell until 2014. Really, don't you people have anything else to do but put half a story up and try to stir up trouble?
Boy, someone is sure touchy! All the poster did was post the link to the letter. He or she made no comment that the sky was falling in. Clue me in as to what in particular struck a nerve.
Why in the world would any MCO or patient want to pay for Lunesta when at the very LEAST they could try this first..... With Lun being approx 60% of the company income you are all screwed when another generic hits the mkt.
The US Food and Drug Administration (FDA) has allowed Actavis to market Zolpidem Tartrate Extended-Release Tablets USP, 12.5mg CIV.
The company has already started distribution of the Zolpidem Tartrate Extended-Release Tablets, the generic equivalent of Ambien CR.
Sanofi-aventis' Ambien CR is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Actavis CEO Doug Boothe said the approval of Zolpidem ER Tablets 12.5 mg enables Actavis to offer both strengths to meet the needs of our customers.
"This approval also underscores Actavis' emphasis and commitment to bringing complex controlled-release products to the marketplace to help improve patient access to pharmaceuticals," Boothe said.
More shit stirring. A heavyweight generic has been available in this market place for YEARS. Adding CR to the mix is not going to a huge shift in what this market does currently. The fact that CR is the same molecule as the other generic will be considered. You should know the market and the industry before you come and try your doom and gloom......
Read the quote more closely it said "you people" it was not in reference to the particular poster, but to everyone in the post. Clue me in when you have a clue.
No shit stirring its SIMPLE business 101. You take two similar products and price one significantly less expensive and see the more expensive one die a slow death. How much has your Lunesta dropped from pregeneric Ambien days? I could answer that for you....ALOT.
You still have not answered my questions....? Why would an MCO or patient pay a significantly higher copay for Lunesta when they could try generic CR first and do well? You and I both know there is VERY little difference between the two drugs minus the small population that in which one doesn't work. I guess I cant blame you for attacking someone who is calling your baby ugly. Time and history will shows how correct I am. If you think Lun sales will not significantly drop you have been severely brainwashed by the pharma industry. Its a good thing so many other HCPs have not.
BTW I have forgotten more about the anti-insomnia/neurology market than you have knowledge in your little pea brain. Now take your $10 co-pay zolpidem instead of your $50 co-pay Lunesta and go to bed.
Not sure why you are posting on this board. Ok just so you are aware, generic CR obviously has eroded some Lunesta business. But to answer your question above a patient would be interested in Lunesta and the $50 off co pay card every month vs generic at $10. In that case its a better product in that patients can get a full night sleep without the much higher side effect issues that are consistent with CR. And, its in many cases going to be cheaper. So while Lunesta will slowly lose business over time it actually had a fantastic year in 2010 and will be very solid over the remaining years of its patent.
I see everyone has been brainwashed at this company! Ask and HCP or better yet and sleep specialist or Neuro 95% of them will tell you there is very little difference between the two drugs regarding efficacy and patient satisfaction. Thanks for reciting what the marketing department tells you to say to your customers word for word.
Oh the rehashed "I have forgot more than you know line"...god you are so original. CR will not significantly erode the market share for Lunesta. That was done when zolpidem went generic in the first place. We are not facing anything different than we are now. Why would an MCO or patient pay a significantly higher copay for Lunesta when they can try generic zolpidem first and do well....oh wait, that's what we face now. Adding CR to the mix does not change the equation. Not attacking you because you are calling my baby ugly, attacking you because you don't have a clue what you are talking about, which leads to one thing...you are here to stir shit.